drug
as of 2026-07-01Memantine
memantine
MeSH D008559
at a glance
small molecule
Pre-approval / investigational in the US
10 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
10
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
NCT04789915Phase 1Recruiting
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04857983Phase 2, Phase 3Completed
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
NCT03860597Phase 4Completed
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697Phase 1, Phase 2Completed
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
NCT02233556—Unknown
Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
NCT02001103Phase 3Unknown
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
NCT00148590Phase 3Terminated
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
NCT00148616Phase 3Terminated
Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms
NCT00757978Phase 4Completed
KOLs & investigators
6
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
trial
trial
indication
indication
indication
indication
indication
KOL
Helge Frieling, Prof., MD
personKOL score 5
Chen-Chung Liu, MD, PhD
personKOL score —
Martin Schaefer, MD
personKOL score —
Ming-Hsien Hsieh, MD, PhD
personKOL score —